Susquehanna International Group
PDLI

Susquehanna International Group’s PDL BioPharma, Inc. PDLI Stock Holding History

Susquehanna International Group’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20,800
Closed -$66K – 12174
2020
Q3 		$66K Sell
20,800
-4,900
-19% -$15.7K ﹤0.01% 10115
2020
Q2 		$75K Sell
25,700
-9,600
-27% -$30.4K ﹤0.01% 9636
2020
Q1 		$100K Buy
35,300
+200
+0.6% +$645 ﹤0.01% 9328
2019
Q4 		$114K Buy
35,100
+15,300
+77% +$44.4K ﹤0.01% 9085
2019
Q3 		$43K Buy
19,800
+7,600
+62% +$20.3K ﹤0.01% 9824
2019
Q2 		$38K Buy
+12,200
New +$39.6K ﹤0.01% 9901
2018
Q3 		– Sell
-23,200
Closed -$54K – 10943
2018
Q2 		$54K Buy
+23,200
New +$64.8K ﹤0.01% 9255
2017
Q3 		– Sell
-11,600
Closed -$29K – 10313
2017
Q2 		$29K Sell
11,600
-57,800
-83% -$133K ﹤0.01% 8981
2017
Q1 		$158K Buy
69,400
+46,400
+202% +$103K ﹤0.01% 8167
2016
Q4 		$49K Buy
+23,000
New +$64.2K ﹤0.01% 9294
2016
Q2 		– Sell
-17,800
Closed -$59K – 10072
2016
Q1 		$59K Buy
17,800
+300
+2% +$935 ﹤0.01% 8624
2015
Q4 		$62K Sell
17,500
-36,200
-67% -$152K ﹤0.01% 9053
2015
Q3 		$270K Sell
53,700
-67,600
-56% -$387K ﹤0.01% 8219
2015
Q2 		$780K Buy
121,300
+37,700
+45% +$253K ﹤0.01% 6724
2015
Q1 		$588K Sell
83,600
-14,500
-15% -$105K ﹤0.01% 6801
2014
Q4 		$756K Buy
98,100
+5,500
+6% +$43.5K ﹤0.01% 6409
2014
Q3 		$692K Sell
92,600
-2,700
-3% -$25.1K ﹤0.01% 6627
2014
Q2 		$923K Buy
95,300
+22,500
+31% +$201K ﹤0.01% 6221
2014
Q1 		$605K Sell
72,800
-20,000
-22% -$171K ﹤0.01% 6414
2013
Q4 		$783K Buy
92,800
+23,100
+33% +$195K ﹤0.01% 5931
2013
Q3 		$556K Buy
69,700
+41,500
+147% +$334K ﹤0.01% 6260
2013
Q2 		$218K Buy
+28,200
New +$220K ﹤0.01% 7311

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Susquehanna International Group's PDLI Position: Q4 2020 in Review

Susquehanna International Group sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 50,978 shares — an estimated $160K sold.

Susquehanna International Group first reported a position in PDLI in Q3 2013 and held it in 24 quarters. The position peaked at $6.86M in Q4 2013. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • Susquehanna International Group reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • Susquehanna International Group sold 50,978 PDL BioPharma, Inc. shares in Q4 2020, an estimated $160K.
  • Susquehanna International Group first reported a position in PDL BioPharma, Inc. in Q3 2013 and held it in 24 quarters.
  • Susquehanna International Group's PDL BioPharma, Inc. position peaked at $6.86M in Q4 2013.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Susquehanna International Group's 13F filing for Q4 2020, filed 16 Feb 2021.